JMJD3 knockdown has been previously shown to decrease cell viability and colony formation in neuroblastoma cell lines, and GSK-J4 is effective in a range of neuroblastoma cell lines by reducing cell viability, inhibiting xenograft growth, and modulating gene expression, including changes in genes associated with neuronal differentiation pathways [13, 14]. Here, KDM6B is linked to neuroblastoma.